Soleno Therapeutics Inc SEC Filings

Soleno Therapeutics Inc. (SLNO) disclosed a new insider reporting status for its Chief Business Officer through a Form 3 filing. This form identifies the individual as an officer of the company and confirms that the filing is made by a single reporting person. The filing states in the remarks that no securities are beneficially owned, meaning the officer reports holding no Soleno shares or derivative securities as of the event date.

Soleno Therapeutics (SLNO) reported an insider ownership update via a Form 3. The filing identifies the reporting person as an Officer (Chief Development Officer) and states that no securities are beneficially owned as of the event date 11/10/2025. The document serves as an initial statement of ownership under Section 16 and was signed by an attorney-in-fact.

Soleno Therapeutics entered an accelerated share repurchase with Jefferies to repurchase $100.0 million of common stock. The Company prepaid $100.0 million and received an initial delivery of 1,511,553 shares, with any remaining shares expected by the end of its first fiscal quarter of 2026. The final share count will be based on the stock’s volume‑weighted average price during the program, less an agreed discount, with settlement adjustments that could require either party to deliver additional shares or, in Soleno’s case, make a cash payment.

In connection with the ASR, Soleno amended its Oxford Finance loan agreement to permit the repurchase and to modify previously committed capacity. Lenders are no longer obligated to fund the $25.0 million Term C Loans or $25.0 million Term D Loans. After the amendment, the remaining $100.0 million of loans is uncommitted and may be made available only upon mutual agreement.

Soleno Therapeutics (SLNO) reported its first profitable quarter as a commercial company. For Q3 2025, product revenue was $66.0 million, driving operating income of $22.1 million and net income of $26.0 million. Year-to-date, product revenue reached $98.7 million. The company began recognizing sales after the FDA approved VYKAT XR in March 2025 to treat hyperphagia in Prader-Willi syndrome and first prescriptions shipped in April.

Liquidity strengthened significantly: cash and cash equivalents were $246.7 million and marketable securities were $309.4 million at September 30, 2025. In July, Soleno completed an underwritten offering of 2,705,882 shares at $85.00 per share for gross proceeds of $230.0 million (approximately $14.3 million in offering costs). Long-term debt outstanding was $50.0 million under the Oxford facility, with additional tranches available subject to terms. Shares outstanding were 53,710,025 as of October 31, 2025.

Soleno Therapeutics (SLNO) disclosed a director equity award. On 10/13/2025, the reporting person was granted 10,046 restricted stock units (RSUs) at $0. Each RSU represents the right to receive one share of common stock.

Vesting: one-third on October 13, 2026 and on each one-year anniversary thereafter, subject to continued service. Beneficial ownership following the grant was 10,046 shares, held directly.

Soleno Therapeutics (SLNO)no securities beneficially owned, with no non-derivative or derivative holdings listed. It was filed by one reporting person and includes an Exhibit 24 Power of Attorney authorizing the signatory.

Soleno Therapeutics (SLNO) expanded its Board and Audit Committee by one seat and appointed Mark W. Hahn as a Class II director, with a term expiring at the 2028 annual meeting. Hahn also joins the Audit Committee.

Hahn brings nearly 30 years of CFO experience, including roles at Verona Pharma (through its first product launch and its approximately $10 billion acquisition by Merck in Oct 2025), Dova Pharmaceuticals (acquired by Sobi for up to $915 million in 2019), and Cempra (led IPO and follow-ons). In connection with his appointment, he received 10,046 RSUs, vesting one-third on Oct 13, 2026 and on each annual anniversary thereafter.